
- The Column-03-09-2015
- Volume 11
- Issue 4
Lung Cancer Breath Test in Clinical Trial
The University of Leicester and Glenfield Hospital in Leicester, UK, are starting a clinical trial into a gas chromatography–field asymmetric ion mobility spectrometry sensor (Owlstone Nanotech Ltd.) for the detection of early-stage lung cancer.
The University of Leicester and Glenfield Hospital in Leicester, UK, are starting a clinical trial into a gas chromatography–field asymmetric ion mobility spectrometry sensor (Owlstone Nanotech Ltd.) for the detection of early-stage lung cancer. Dr Salman Siddiqui, a clinical senior lecturer and adult chest physician at the University of Leicester and Leicester’s Hospitals, said: “Lung cancer has one of the lowest 5-year survival rates of all cancers; however, early diagnosis can greatly improve a patient’s prognosis. Current diagnostic procedures such as a chest X-ray, CT scan, and bronchoscopy are costly and not without risks so the benefits of a non-invasive, cheaper alternative are clear.”
Articles in this issue
over 10 years ago
Finding Answers with Foodomicsover 10 years ago
ISCC and GC×GC 2015over 10 years ago
The 2015 LCGC Awards: Part 1over 10 years ago
Determining Child Phthalate Exposureover 10 years ago
Thermo Fisher Scientific Buys Advanced Scientifics, Inc.over 10 years ago
Fraudulent Dietary Supplement Analysisover 10 years ago
PerkinElmer and Waters Collaborateover 10 years ago
Vol 11 No 4 The Column March 09, 2015 Europe and Asia PDFover 10 years ago
Vol 11 No 4 The Column March 09, 2015 North American PDFNewsletter
Join the global community of analytical scientists who trust LCGC for insights on the latest techniques, trends, and expert solutions in chromatography.





